Twenty-three child patients with immunothrombocytopenic purpura ITP were treated with high doses of immunoglobulins for intravenous application. The dose applied was 400 mg/kg during five consecutive days. The immunological status of all patients was determined previously, and beside the normal values of the IgG serum, a deficit of the IgG2 subclass was discovered in 12 patients. The therapy effect was satisfactory in 19 patients, and 4 had an absence of a satisfactory response to therapy. There was an interesting observation that all patients with a good response to therapy had a deficit of the IgG2 subclass, while with all the other patients without a satisfactory response to therapy the, IgG2 subclass had normal values. On the basis of the results observed it can be concluded that i.v. immunoglobin therapy in high doses has it's place in the immunothrombocytopenia treatment of children, and especially of patients with an IgG2 subclass deficit.

Download full-text PDF

Source

Publication Analysis

Top Keywords

igg2 subclass
16
high doses
12
response therapy
12
immunothrombocytopenic purpura
8
normal values
8
deficit igg2
8
satisfactory response
8
patients
7
therapy
5
[personal experience
4

Similar Publications

Pemphigus is a group of autoimmune bullous diseases mediated by autoantibodies most often of the immunoglobulin G class, subclasses immunoglobulin G1, and immunoglobulin G4 (IgG4), directed against desmosomal adhesion proteins of keratinocytes. This study aimed to evaluate IgG4 immunoreactivity on paraffin sections using immunohistochemistry in patients with pemphigus as a diagnostic test. Fifty formalin-fixed paraffin-embedded specimens from patients with pemphigus were selected.

View Article and Find Full Text PDF

An engineered Palivizumab IgG2 subclass for synthetic gp130 and fas mediated signaling.

J Biol Chem

January 2025

Institute of Biochemistry and Molecular Biology II, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany. Electronic address:

Recently, we phenocopied Interleukin (IL-)6 signaling using the dimerized single-chain variable fragment (scFv) derived from the respiratory syncytial virus (RSV) IgG1-antibody Palivizumab (PLHFc) to activate a Palivizumab anti-idiotypic nanobody (AIP)-gp130 receptor fusion protein. Palivizumab was unable to activate STAT3 signaling, so we aimed to create a similar ligand capable of triggering this pathway. Here, we created three variants of the ligand called PLH0Fc, PLH4Fc and PLH8Fc by shortening the spacer region connecting PLH and Fc from 23 amino acids in PLHFc to 0 amino acids or expanding it by rigid linkers of 4 or 8 alpha helical loops, respectively.

View Article and Find Full Text PDF

Conformational Antibodies to Proteolipid Protein-1 and Its Peripheral Isoform DM20 in Patients With CNS Autoimmune Demyelinating Disorders.

Neurol Neuroimmunol Neuroinflamm

March 2025

Neuroimmunology Laboratory and Neuroimmunology Research Section, IRCCS Mondino Foundation, Pavia, Italy.

Background And Objectives: Antibodies to proteolipid protein-1 (PLP1-IgG), a major central myelin protein also expressed in the peripheral nervous system (PNS) as the isoform DM20, have been previously identified mostly in patients with multiple sclerosis (MS), with unclear clinical implications. However, most studies relied on nonconformational immunoassays and included few patients with non-MS CNS autoimmune demyelinating disorders (ADDs). We aimed to investigate conformational PLP1-IgG in the whole ADD spectrum.

View Article and Find Full Text PDF

Background: Recombinant Necator americanus Glutathione-S-Transferase-1 (Na-GST-1) formulated on Alhydrogel (Na-GST-1/Alhydrogel) is being developed to prevent anemia and other complications of N. americanus infection. Antibodies induced by vaccination with recombinant Na-GST-1 are hypothesized to interfere with the blood digestion pathway of adult hookworms in the host.

View Article and Find Full Text PDF

In silico prediction and experimental evaluation of LIP3228 of pathogenic Leptospira as a potential subunit vaccine target against leptospirosis.

Biochem Biophys Res Commun

January 2025

Chula Vaccine Research Center (Chula VRC), Center of Excellence in Vaccine Research and Development, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand; Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand. Electronic address:

A protein subunit vaccine comprising conserved surface-exposed outer membrane proteins (SE-OMPs) is considered a promising platform for leptospirosis vaccine. The search for novel vaccine candidates that confer high protective efficacy against leptospirosis is ongoing. The LIP3228 protein was previously identified as a conserved and abundant SE-OMP with the potential to serve as an effective vaccine candidate.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!